Combining immunotherapy with chemotherapy shows promise in enhancing survival rates for extensive-stage small cell lung ...

It had been hoped that RA patients might actually benefit more from these drugs, known as immune checkpoint inhibitors (ICIs) ...

Boehringer Ingelheim’s drug candidate for human epidermal growth factor receptor 2 (HER2)-mutated non-small cell lung cancer ...

Topline data were announced from a phase 3 trial evaluating tarlatamab for the treatment of SCLC in patients who progressed on or after a single line of platinum-based chemotherapy.

Julie Brahmer, MD, discusses the unique features of the phase 3 CheckMate 9LA trial in patients with metastatic non–small cell lung cancer.

A combination of pertuzimab and Enhertu can slow disease progression and improve survival in people with HER2-positive ...

A New England Journal of Medicine study published April 27 found success in administering dostarlimab, an immunotherapy drug, ...